|会社名||Selecta Biosciences Inc （セレクタ・バイオサイエンシズ）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 セレクタ・バイオサイエンス(Selecta Biosciences Inc.)は臨床段階のバイオ医薬品会社である。同社は合成ワクチン粒子（SVP）技術を使用して、希少疾患および重症疾患を治療するために免疫系を調節するように設計された標的療法を発見・開発する。同社はヒト疾患の治療および予防のためのナノ粒子免疫調節薬の研究・開発に従事する。同社の製品候補は、臨床および前臨床開発の各段階にある。そのSVP技術は、生物分解性ナノ粒子に免疫調節物質を封入し、抗原特異的な免疫寛容を誘導し、生命維持生物製剤に応答する抗薬物抗体（ADA）の形成を軽減する。主要製品候補であるSEL-212は、痛風の生物学的治療薬として設計された治療用酵素とそのSVP技術の組み合わせである。 セレクタ・バイオサイエンシズは米国のバイオ医薬品企業。臨床段階で、合成粒子ワクチン(SVP)技術を利用し難病の免疫療法による治療の開発に従事。同社のSVP技術は、患者の免疫系と合わない場合に、免疫調整物質を生物分解可能なナノ粒子にカプセル化するテクノロジ―。本社はマサチュ―セッツ州ウォ―タ―タウン。 Selecta Biosciences Inc. is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. The company's first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.|
|本社所在地||480 Arsenal Way Watertown MA 02472 USA|
|代表者氏名||Omid Farokhzad オミッド・ファロクザド|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Selecta Biosciences Inc revenues decreased from $163K to $0K. Net loss increased 12% to $34.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 15% to $24.4M (expense) Stock-based Compensation in SGA increase of 60% to $1.3M (expense).|
Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer 2021/09/20 12:00:00 Intrado Digital Media
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer.
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference 2021/09/09 12:00:00 Intrado Digital Media
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selectas Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23 rd Annual Global Investment Conference to be held September 13-15, 2021.
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins 2021/09/08 12:00:00 Intrado Digital Media
- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions-
Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021 2021/07/08 12:00:00 Intrado Digital Media
WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selectas Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 to be held virtually, July 14-15.
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors 2021/06/24 12:00:00 Intrado Digital Media
WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Nishan de Silva, M.D. to its Board of Directors. Dr. de Silva will provide strategic guidance and operational insights as Selecta continues to advance its clinical pipeline.
After recent weakness, gene therapy space offers a compelling opportunity: BTIG 2021/06/15 20:07:33 Seeking Alpha
Selecta Biosciences Stock Is Trading Lower After Gaining Total Rights To MMA Program From AskBio 2021/04/29 14:52:34 Benzinga
Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences Inc (NASDAQ: SELB ). MMA program includes gene therapy candidate MMA-101 and ImmTOR for the treatment of … Full story available on Benzinga.com
Selecta Biosciences (NASDAQ:SELB) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS 2021/03/13 01:50:43 Transcript Daily
Selecta Biosciences (NASDAQ:SELB) announced its earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02), MarketWatch Earnings reports. NASDAQ:SELB traded up $0.37 during mid-day trading on Friday, hitting $4.27. The company had a trading volume of 1,437,968 shares, compared to its average volume of 2,141,261. […]
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs 2021/02/04 12:21:57 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arcus Biosciences Inc (NYSE: RCUS ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) BioVie Inc (NASDAQ: BIVI ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) CorMedix Inc. Common Stock (NASDAQ: CRMD ) F-Star Therapeutics Inc (NASDAQ: FSTX ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Glaukos Corp (NYSE: GKOS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) ( announced a deal to be bought by Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) for $7.2 billion) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Immunome Inc (NASDAQ: IMNM ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) Jounce Therapeutics Inc (NASDAQ: JNCE ) MannKind Corporation (NASDAQ: MNKD ) Morphic Holding Inc (NASDAQ: MORF ) Myriad Genetics, Inc.
Selecta Biosciences : Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy | MarketScreener 2021/01/06 13:00:15 MarketScreener
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8… | January 6, 2021
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 セレクタ・バイオサイエンシズ SELB Selecta Biosciences Inc.）